Theriva Biologics, Inc. (TOVX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Theriva Biologics, Inc. on August 15, 2024. The Company is a Nevada corporation listed on the NYSE American under the symbol "TOVX". The filing reports a material modification to the rights of security holders and amendments to the Articles of Incorporation regarding a reverse stock split.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on capital structure changes.
Material Changes
- Reverse Stock Split: The Board of Directors approved a 1-for-25 reverse stock split of authorized, issued, and outstanding common stock.
- Share Count Reduction: Outstanding shares will be reduced from 25,131,230 to approximately 1,005,249 shares.
- Effective Date: The split is anticipated to be effective at 12:01 a.m. Eastern Time on August 26, 2024.
- Fractional Shares: No fractional shares will be issued. Stockholders entitled to fractional shares will receive one whole share rounded up, with no cash payment for the fractional portion.
- Identification: The trading symbol remains "TOVX". The new CUSIP number is 87164U 508.
Outlook, Risks, and Management Commentary
Purpose: The reverse stock split is being effected to ensure the Company meets the per-share price requirements of the NYSE American listing standards.
Management Commentary: The Company issued a press release on August 16, 2024, announcing the split. No specific financial guidance or risk factors beyond the listing compliance necessity were detailed in this specific filing.
Investor Verification Checklist
- Verify the effective date of the reverse stock split (August 26, 2024) with the NYSE American.
- Confirm the new CUSIP number (87164U 508) with your brokerage to ensure proper account updates.
- Review the treatment of fractional shares to understand if your specific holding will be rounded up to a whole share.
- Monitor the post-split share price to ensure it meets the NYSE American minimum bid price requirement.